Insurance & Health
Glaxo Avandia Restrictions Should Be Eased, Panel Says
The perceived heart risks that torpedoed sales of GlaxoSmithKline Plc’s best-selling diabetes pill Avandia may have been overstated and restrictions... Read More
More Insurance & Health News
- Needle-Tenderized Steaks to Require New Labels in U.S.
- Two-Dose Contraceptive Must Be Made Available to All Ages
- Celgene’s Revlimid Wins Expanded Use for Blood Cancer
- Diabetes Drug From Bristol and Astra Wins U.K. Panel’s Backing
- Oklahoma Tornado Cost Insurers as Much as $3.5 Billion
- Merck Insomnia Drug Safe Only in Lower Doses, Panel Says
- Boston Scientific’s Lotus Aortic Valve Has Promise in Study
- Medtronic Device Safely Fixes Aortic Value in Study
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- Lundbeck-Takeda Drug Fights Depression Better at Higher Dose
- Club-Drug Ketamine Relieves Depression in Largest Patient Study
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Children’s Mental Illness Costs $247 Billion, U.S. Says
- Bristol-Myers Drug Cocktail Stymies Melanoma Tumors
- Gene-Testing Dispute Focuses on How Much a Patient Should Know
- Personal Finance Videos
- Real Cost of
- Money Gallery
Advertisements
Rate this Page